Abstract
The acute-phase response is the answer of the organism to a disturbance of its homeostasis and is characterized by dramatic changes in the concentration of some plasma proteins defined as acute-phase proteins. In recent years several data have shown that interleukin-6 (IL-6) is the major inducer of acute-phase protein synthesis in human hepatocytes. Recently, we demonstrated higher IL-6 serum levels in head and neck cancer (HNC) patients than in healthy subjects. In the present study we examined the relationship between levels of IL-6 and of several acute-phase proteins, including C-reactive protein (CRP), α1-antitrypsin (AAT), αl-acid glycoprotein (AAG), haptoglobin (HPT) and fibrinogen. Eighteen patients were studied and had squamous cell carcinoma of the larynx (n = 9), oral cavity (n = 4), oropharynx (n = 3) and hypopharynx (n = 2). Proteins were measured at three time points before and three time points after surgery. Significant (P < 0.0001) relationships were found between IL-6 and CRP (r = 0.69), and fibrinogen (r = 0.51), whereas no correlation was found with AAT (r = 0.13, P = 0.56), AAG (r = 0.38; P = 0.07) and HPT (r = 0.16; P = 0.46). These data strongly suggest that IL-6 may play a key role in acute-phase protein synthesis in HNC and in regulation of the complex host response to malignancies.
Similar content being viewed by others
References
Aoles EW, Hinson A, Chapuls-Cellier C, Arnaud P (1982) Modulation of the immune response by plasma protease inhibitors. Scand J Immunol 15:109–113
Arora P, Miller HC (1978) Alpha-1 antitrypsin is an effector of immunologic states. Nature 274:589–590
Baskies AM, Chretien PB, Weiss JF, Makuch RW, Beveridge RA, Catalona WJ, Spiegel HE (1980) Serum glycoprotein in cancer patients: first report of correlations with in vitro and in vivo parameters of cellular immunity. Cancer 45:3050–3060
Berek JS, Chung C, Kabli K, Watson JW, Knox RM, Martinez-Mara O (1991) Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol 164:1038–1043
Blay JV, Negriev S, Combare V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF, Philip T, Favrot M (1992) Serum level of interleukin-6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res 52:3317–3322
Fearon KC, McMillan DC, Preston T, Winstanley FP, Cruickshank AM, Shenkin A (1991) Elevated circulating interleukin-6 is associated with an acute phase response but reduced fixed hepatic protein syntesis in patients with cancer. Ann Surg 213:26–31
Gallo O, Gori AM, Attanasio M, Martini F, Fini-Storchi O, Abbate R (1992) Interleukin-6 serum level and monocyte production in head and neck cancer. Br J Cancer 65:479–480
Gallo O, Bani D, Toccafondi G, Almerigogna F, Fini-Storchi O (1992) Characterization of a novel cell line from pleomorphic adenoma of the parotid gland with myoepithelial phenotype and producing interleukin-6 as an autocrine growth factor. Cancer 70:559–568
Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H (1987) Interferon beta-2/B-cell stimulatory factor type 2 share identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute-phase protein response in liver cells. Proc Natl Acad Sci USA 84:7251–7255
Geiger T, Andus T, Klapproth J, Hirano T, Kishimoto TA, Heinrich PC (1988) Induction of rat acute-phase proteins by interleukin-6 in vivo. Eur J Immunol 18:717–721
Heinrich PC, Castell JV, Andst T (1990) Interleukin-6 and the acute phase response. Biochem J 265:621–636
Jablons DM, Mule JJ, McIntosh JK, Sehgal PB, May L, Huang CM, Rosenberg SA, Lotze MT (1989) IL-6/IFN-beta2 as a circulating hormone: induction by cytokine administration in humans. J Immunol 142:1542–1547
Kirnbauer R, Kock A, Schwarz T, Urbanski A, Krutmann J, Borth W, Damm D, Shipley G, Ansel JC, Luger TA (1989) IFN-beta2, B cell differentiation factor 2, or hybridoma growth factor (IL-6) is expressed and released by human epidermal cells and epidermoid carcinoma cell lines. J Immunol 142: 1922–1928
Kishimoto T (1989) The biology of interleukin-6. Blood 74:1–5
reciki T, Leluk M (1992) Acute-phase reactant proteins - an aid to monitoring surgical treatment of laryngeal carcinoma. J Laryngol Otol 106:613–615
Lamat N, Zlontnick AY, Shtiller R, Bar I, Merin G (1992) Serum level of IL-1, IL-6 and TNF in patients undergoing coronary artery by-pass grafts or cholecystectomy. Clin Exp Immunol 89:255–260
Luger TA, Krutmann J, Kirnbauer R, Urbanski R, Schwartz T, Klappacher G, Kock A, Micksche M, Malejczyk J, Schauer E, May LT, Sehgal PB (1989) IFN beta-2/IL-6 augments the activity of human natural killer cells. J Immunol 143:1206–1209
Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T, Kishimoto T (1989) Il-6 functions as an autocrine growth factor in renal carcinomas. FEBS Lett 250:607–610
Mulé JJ, McIntosh JK, Jablons DM, Rosemberg SA (1990) Antitumor activity of recombinant IL-6 in mice. J Exp Med 171:629–636
Nakazaki N (1992) Preoperative and postoperative cytokines in patients with cancer. Cancer 70:709–713
Nishimoto N, Yoshizaki K, Tagon H, Monden M, Kishimoto S, Hirano T, Kishimoto T (1989) Elevation of serum interleukin-6 prior to acute-phase proteins on the inflammation by surgical operation. Clin Immunol Immunopathol 50:399–401
Petersen CM, Ejlersen E, Moestrup SK, Jensen PH, Sand O, Sottrup-Jensen (1989) Immunosuppressive properties of electrophoretically “slow” and “fast” form α 2-macroglobulin: effects on cell mediated cytotoxicity and (allo-) antigen-induced T cell proliferation. J Immunol 142:629–632
Pordagor A, Tzehoval E, Katz A, Vadai E, Revel M, Feldman M, Eisenbach L (1992) Interleukin-6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 52:3679–3686
Revel M (1991) Antitumor potentials of interleukin-6. Interferons Cytokines 19:5–8
Revel M, Chen L, Novivk D, Shulman LM, Gotthelf Y, Cohen B, Raber J, Chebath J, Michalevicz R (1989) The growth-promoting,differentiative and cytostatic properties of interleukin-6. Proc Am Assoc Cancer Res 31:499–500
Takai Y, Wong GG, Clark SC, Bucakoff SJ, Hermann SH (1988) B cell stimulatory factor-2 is involved in in vitro induction of cytotoxic T lymphocytes. J Immunol 140:508–514
Tosato G, Pike S (1988) Interferon Beta2/IL-6 is a costimulant for human T lymphocytes. J Immunol 141:1556–1562
Tritarelli E, Rocca E, Testa U, Boccoli G, Camagna A, Calabresi F, Peschle C (1991) Adoptive immunotherapy with high-dose IL-2: kinetics of circulating progenitors correlation with IL-6, GM-CSF level. Blood 77:741–749
Utsumi K, Takai Y, Tada T, Ohezeki S, Fujiwara H, Hamaoka T (1990) Enhanced production of IL-6 in tumor-bearing mice and determination of cells responsible for its augmented production. J Immunol 145:397–403
Von Clauss A (1957) Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 17:237–246
Wolf T, Chretien PB, Elias GE, Makuch RW, Baskies AM, Spiegel HE, Weiss JF (1979) Serum glycoproteins in head and neck squamous carcinoma. Am J Surg 138:489–500
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gallo, O., Gori, A.M., Attanasio, M. et al. Interleukin-6 and acute-phase proteins in head and neck cancer. Eur Arch Otorhinolaryngol 252, 159–162 (1995). https://doi.org/10.1007/BF00178104
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00178104